About TD Vaccines
TD Vaccines A/S is a Danish biotechnology company established in November 2009. The company is focused on the development of vaccines to protect against travellers’ diarrhoea (TD). Every year, millions of tourist and business travellers visit destinations in Asia, Africa and Latin America and around half of these succumb to TD.
TD Vaccines’ lead programme is ACE527, an oral ETEC vaccine to protect against ETEC (Enterotoxigenic E Coli). ACE527 has finished Phase I trials in the US and will enter Phase 2 during first half of 2010.
Earlier in development, at a preclinical stage, is an oral combination vaccine, ACE920, designed to protect against ETEC and Campylobacter infections.
TD Vaccines is backed by the Danish venture capital investors Sunstone Capital and LD Equity and headed up by Ms Ingelise Saunders, formerly CEO of ACE BioSciences.
The TD Vaccines web site can be found at www.tdvaccines.com.
